The prescribing information for Brixocatib tablets indicates that there are no absolute contraindications, but careful assessment of risks and benefits is still required in patients with special physiological conditions.
I. Contraindications and General Precautions
1. No Absolute Contraindications
(1) The prescribing information for Brixocatib tablets does not list any absolutely prohibited situations.
(2) There are no known contraindications to drug components, but if there is a previous allergy to any excipient in this product, use should be avoided.
2. Vaccination-Related Contraindications
(1) Live vaccines (such as MMR, varicella, oral rotavirus vaccine, etc.) should be avoided during treatment.
(2) Before receiving any vaccine, healthcare providers must be actively informed that the patient is taking this product.
3. General Safety Tips
(1) Although there are no absolute contraindications, baseline assessments of skin, oral cavity, liver function, and blood pressure must be fully evaluated before treatment.
(2) In the presence of severe systemic infection or immunodeficiency, the risks and benefits should be weighed by a specialist physician.
II. Key Points for Special Populations
1. Pregnant Women
(1) There are currently no adequate human pregnancy safety data; animal studies at high doses have observed skeletal malformations.
(2) Use only when clearly needed and the potential benefit outweighs the potential risk to the fetus.
2. Breastfeeding Women
(1) It is unknown whether this product is excreted in human milk, and the effect on nursing infants is unknown.
(2) The benefits of breastfeeding, the maternal need for treatment, and the potential risk to the infant should be considered comprehensively.
3. Pediatric Population
(1) Efficacy and safety have been established in adolescent patients aged 12 years and older.
(2) Safety and efficacy in children under 12 years of age have not been established, and use is not recommended.
(3) The pediatric dosage is the same as that for adults (10 mg or 25 mg once daily), with no weight-based adjustment needed.
4. Elderly Population
(1) No differences in efficacy or safety have been observed between patients aged 65 years and older and younger adults.
(2) No dose adjustment is needed based on age, but elderly patients often have multiple comorbidities, requiring enhanced comprehensive monitoring.
(3) During treatment, special attention should be paid to blood pressure, renal function, and skin changes.
5. Patients with Hepatic or Renal Impairment
(1) No dose adjustment is needed for patients with mild, moderate, or severe hepatic impairment.
(2) No dose adjustment is needed for patients with mild, moderate, or severe renal impairment.
(3) However, patients with severe hepatic or renal impairment should still use the product under physician guidance and have relevant parameters monitored regularly.
III. Pre-Treatment Risk Assessment and Communication Points
1. Detailed Medical History and Concomitant Medications
(1) At the visit, a complete medical history should be provided, including dermatological history, gingival disease, liver disease, and hypertension.
(2) Provide a list of all current prescription drugs, over-the-counter medications, and dietary supplements, with special note of whether clarithromycin, verapamil, or rifampicin are being used.
2. Baseline Tests
(1) Before initiating treatment, it is recommended to complete: comprehensive liver function tests, renal function, blood pressure measurement, dental/oral examination, and dermatological baseline assessment.
(2) Patients with a history of skin cancer or multiple nevi should undergo a specialized dermatological examination and have a file established.
3. Dynamic Evaluation During Treatment
(1) Regular monitoring of liver function and blood pressure should be performed; if abnormal fluctuations occur, seek medical attention promptly.
(2) Any new rash, gingival bleeding, or hair loss should be actively reported to the physician rather than stopping the medication on one's own.
(3) It is advisable to maintain personal health records to provide objective data during follow-up visits.
